Fill out this medical information card with the contact information of your/your child's doctor. Keep it with you, or have your child keep it on them, while on BLINCYTO® (blinatumomab) treatment.

Fold

About me:

Name

Phone

My parent or caregiver:

Name

Phone

Medical information card

Patient is receiving BLINCYTO® (blinatumomab) for the treatment:

Fill out this medical information card. You can keep your important health care contact information in one place here.

There is also information on some possible side effects.

AMGEN®

BLINCYTO® is a registered trademark of Amgen Inc.
© 2023-2025 Amgen Inc. All rights reserved. USA-103-81852 01/25

WHAT IS BLINCYTO® (blinatumomab)?

BLINCYTO® is a prescription medicine used to treat adults and children 1 month and older with:

- **B-cell precursor acute lymphoblastic leukemia (ALL) in remission when only a small number of cancer cells remain in the body (minimal residual disease)**
- **B-cell precursor ALL that has come back or did not respond to previous treatments**
- **Philadelphia-chromosome negative B cell precursor ALL in the consolidation phase of chemotherapy treatment with multiple phases**

ALL is a cancer of the blood in which a particular kind of white blood cell is growing out of control.

It is not known if BLINCYTO® is safe and effective in children less than 1 month of age.

BLINCYTO® (blinatumomab) for injection 35 mcg single-dose vial

Fold

About my doctor:

Name

Phone

Learn more at www.BLINCYTO.com

Fold

Cytokine release syndrome and infusion reactions

Symptoms may include:

- Fever
- Tiredness or weakness
- Dizziness
- Headache
- Low blood pressure
- Nausea
- Vomiting
- Chills
- Face swelling
- Wheezing or trouble breathing
- Skin rash

Neurologic problems

Symptoms may include:

- Seizures
- Difficulty in speaking or slurred speech
- Loss of consciousness
- Trouble sleeping
- Confusion and disorientation
- Loss of balance
- Headache
- Difficulty with facial movements, hearing, vision, or swallowing
- Tremors

People with Down Syndrome may have a higher risk of seizures with BLINCYTO® treatment.

IMPORTANT NOTE FOR HEALTH CARE PROFESSIONALS:

Do not flush the BLINCYTO® (blinatumomab) infusion line or intravenous catheter, especially when changing infusion bags. Flushing when changing bags or at completion of infusion can result in excess dosage and cause complications. When administering via a multi-lumen venous catheter, infuse BLINCYTO® (blinatumomab) through a dedicated lumen.

Please contact your prescribing provider with any questions

BLINCYTO® (blinatumomab) may cause serious side effects that can be severe, life-threatening, or lead to death, including:

Please contact your prescribing provider with any questions.

Please see BLINCYTO® full Prescribing Information, including BOXED WARNINGS and Medication Guide.